Tablets or capsules taken orally remain one of the most effective means of treatment available. The effectiveness of such dosage forms relies on the drug dissolving in the fluids of the gastrointestinal tract prior to absorption into the systemic circulation. The present study reveals the evaluation of four marketed sample of Telmisartan tablets. The main aim of the study is to conduct dissolution test on the tablets to determine the compliance with a given official monograph. Four different marketed samples of Telmisartan were purchased from local market. The Telmisartan tablets were evaluated for the various in-vitro tablet properties such as thickness, hardness, friability, weight variation, drug content, disintegration time and dissolution rate. In-vitro dissolution test is conducted on four different brands of telmisartan tablets to assess their equivalency. All the four marketed samples of Telmisartan have shown good tablet properties and comply with the pharmacopoeial specification. The in-vitro dissolution showed the 80% drug release within one hour from all the four brands which complies with the specification of pharmacopoeia.
INTRODUCTION
Seventy-six percent of patients achieve a full response to treatment (Diastolic BP ≤ 90mm Hg or ≥ 10mm Hg reduction) and 22% had an inadequate response to telmisartan therapy (Diastolic BP > 90mm Hg or < 7mm Hg reduction). Overall, heart rate was reduced from 78.0 to73.8 beats/min after 6 months of treatment. The dosage was increased in 24% of patients because of the insufficient BP reduction with the lower dosage Global tolerability was rated as very good, good, moderate or poor in 75%, 22%, 1% and 1% of patients, respectively. There were no significant differences in global tolerability ratings between the patient groups. Telmisartan had only a minor or no effect on serum creatine levels across all patient groups. Serious adverse events were reported in 0.06% of patients and included death in 6 patients. None of the deaths were considered drug-related. [1] [2] [3] [4] The solubility/dissolution behavior of a drug is key determinant to its oral bioavailability, being the rate-limiting step to absorption of drugs from the gastrointestinal tract. Consequently poor solubility has low bioavailability increase in dosage, large inter and intra-subject variation in blood drug concentrations under fed versus fasted conditions. [5] [6] [7] A drug may be a substance for diagnosis, cure, mitigation, prevention or treatment of disease in human beings or animals, which act by altering any structure or function of body of human being or animal. Every year number of drugs is introduced into the market. The total drug absorption into the body when administered i.e. In-vivo and dissolution tests is used to determine the absorption of drug In-vitro i.e. IVIVC absorption of the drug. [9] [10] [11] [12] [13] Drug absorption from a solid dosage form after oral administration depends on the release of the drug substance from the drug product, the dissolution or solubilization of the drug under physiological conditions, and the permeability across the gastrointestinal tract. Because of the critical nature of the first two of these steps, In-vitro dissolution may be relevant to the prediction of In-vivo performance. Based on this general consideration, In-vitro dissolution tests for immediate release solid oral dosage forms, such as tablets and capsules, are used to 1) Assess the lot-to-lot quality of a drug product;
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3) Ensure continuing product quality and performance.
After certain changes, such as changes in the formulation, the manufacturing process, the site of manufacture, and the scale-up of the manufacturing process. Current knowledge about the solubility, permeability, dissolution, and pharmacokinetics of a drug product should be considered in defining dissolution test specifications for the drug approval process. This knowledge should also be used to ensure continued equivalence of the product, as well as to ensure the product's similarity under certain scale-up and postapproval changes. [14] [15] [16] New drug applications (NDAs) submitted to the Food and Drug Administration (FDA) contain bioavailability data and in vitro dissolution data that, together with chemistry, manufacturing and controls (CMC) data, characterize the quality and performance of the drug product. In-vitro dissolution data are generally obtained from batches that have been used in pivotal clinical and/or bioavailability studies and from other human studies conducted during product development. Acceptable bioequivalence data and comparable In-vitro dissolution and CMC data are required for approval of abbreviated new drug applications (ANDAs). The In-vitro specifications for generic products should be established based on a dissolution profile. For new drug applications, as well as generic drug applications, the dissolution specifications should be based on acceptable clinical, bioavailability, and/or bioequivalence batches. [17] [18] [19] [20] [21] [22] 
MATERIAL AND METHODS

Chemicals and Reagents
Potassium dihydrogen phosphate, concentrated hydrochloric acid, sodium hydroxide were used as received. Whitman Filter Paper (Ashless, 1440-110, Grade 40 circles, 110 mm) and Distilled water were utilized for studies.
The dissolution media were prepared as per USP procedure. Immediate release Telmisartan 40 mg tablets of four different brands were purchased from different local retail pharmacists at shikrapur local market Pune. Products were codified as Brand A, Brand B, Brand C, and Brand D.
The following commercial tablets of Telmisartan 40 mg were taken for the study: 
Methods
1) Analytical Method Development
For dissolution study, the drug was analyzed by UV Spectroscopy at λmax of 291 nm and standard curves was plotted for respective buffers.
Preparation of Standard Curve
Standard Curve at pH 7.5
Telmisartan 10 mg was accurately weighed. The drug was dissolved in methanol and volume was made to 100 ml to obtain a stock solution of 100 μg/ml. Different aliquots of this solution were diluted suitably with pH 7.5 buffer to give solutions containing 2, 4, 6, 8, 10, 12 and 14 μg/ml of Telmisartan. The absorbance of these solutions was measured at 291 nm on UV-Visible spectrophotometer against pH 7.5 buffers as blank. The linearity was established over the entire concentration range by plotting graph of absorbance versus corresponding concentrations. The data was statistically evaluated using linear regression analysis.
Evaluation of Marketed Telmisartan Tablet
Thickness: The thickness of the tablets were study by using Vernier Caliper Drug Content: Weight tablets (5) were powdered using a glass mortar and pestle. An accurately weighed quantity of tablet containing about 250mg of telmisartan is dissolve in methanol and taken in to 100 ml volumetric flask. Then pipette out 10 ml of above solution then diluted up to 50 ml. From this standard solution again , 5 ml is pipette out , diluted to 50 ml with 0.1 N HCL, resulting solution was measured at 296 nm and drug content was calculated against 0.1 N HCL as blank.
Determination of Hardness and Friability
Hardness of the tablets was determined using a Monsanto Hardness Tester.
About 10 previously weighed tablets were placed in a friability apparatus, which was rotarod at 100 revolution and the tablets were reweighed. The percent friability was calculated using formula.
Determination of Disintegration Time
The tablets were placed in each of the six tubes of the basket of the disintegration apparatus using water as the immersion fluid. The test was carried out for 30 minutes. The disintegration time was noted when no residue of the unit, except fragments of insoluble coating, remained on the screen of the apparatus.
Dissolution Profile Study OR In-vitro release studies
The In-vitro dissolution studies of the marketed conventional IR tablets and the developed SR tablets were carried out using USP type II apparatus (Electrolab, Pune, India) at 75 rpm. The dissolution medium consisted of 900 ml of distilled water maintained at 37 ± 0.5°C. The drug release at different time intervals was measured using an UV visible spectrophotometer. It was made clear that none of the ingredients used in the matrix formulations interfered with the absorbance of the drug. The release studies were conducted for three tablets in a batch and the mean values were plotted against time. Dissolution test by USP paddle apparatus. The In-vitro dissolution study is carried out using apparatus II (paddle). The dissolution jars are cleaned with a mild detergent and then rinsed with distilled water and dry to room temperature. 900 ml of dissolution medium is transferred into the dissolution jars and are placed in the test assembly which is maintained at 37 o C which is given an
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The rpm is set to 75. The test sample is introduced inside the dissolution jar and the test assembly is brought down to the Static position and the medium is stirred at 100rpm. 10 ml of the samples are withdrawn at various time intervals such as 0 minutes, 10 minutes, 20 minutes, 30 minutes, 40 minutes, and 50 minutes using a graduated pipette and transfer it immediately to clean, dried and labeled test tubes. The equal volume of fresh dissolution medium is replaced after each sampling and maintained at the correct temperature. The sample withdrawn is diluted 10 by buffer and the absorbance is measured at 291nm for 0.1N HCl and 294 nm for phosphate buffer at pH 7.5. 10 ml of sample is withdrawn at the end of 30 minutes from each of the test jar, using a graduated pipette and it is filtered if necessary.
It is then transferred to a cleaned, dried and labeled test tube. The sample is diluted by buffer and the absorbance is measured at 291nm for 0.1N HCl and 294 nm for phosphate buffer at pH 7.5. The cumulative percentage of released is calculated using the formula.
Cumulative % release
Where, Pt = Percentage release at time t' P (t -1) = Percentage release previous to't'. 
Comparison of Different Brands of Telmisartan Tablet
Tablets containing Telmisartan (40 mg), was used and compared with the each other suggested by FDA. Dissolution profiles of the four different brands of Telmisartan containing 40 mg of the drug would be compared. These dissolution profiles are studied in presence of 7.5 pH phosphate buffer and the percentage release which is calculated by absorbance.
Formula for determination of percentage of release of drug Telmisartan from In-vitro dissolution testing:
Concentration of drug (μg/ml) = (slope × absorbance) ± intercept 
Linearity
The Telmisartan drug shows maximum absorbance at 291 nm in the concentration range of 2-14 µg/ml. as shown in (Table no. 3) The linearity was observed in concentration range of 2-14 µg/ml. concentration versus respective absorbance at 291 nm was plotted. The regression coefficient was found to be 0.9998. as shown in (Fig.2) . 
Evaluation Parameter
All the tablet formulations showed acceptable pharmacotechnical properties and complied with the range specified by US Pharmacopoeia for Disintegration, weight variation, friability, hardness. 
Dissolution Test
The In-vitro drug release characteristics of the developed marketed tablets were studied. Dissolution data for all the experiments were highly reproducible and hence only the average values were plotted. The dissolution of the marketed tablets indicated that more than 80% of the drug is released within 1 h, which complies with the pharmacopoeial specifications. In all the batches, we observed that as the polymer concentration increases, the drug release rate decreases. The percentage releases of the all brands are plotted against the time. Which is shows in (Fig.3) . 
CONCLUSION
In vitro dissolution methods are developed to evaluate the potential in vivo performance of a solid oral dosage form, and as quality control tests demonstrating the appropriate performance of drugs products.
The in vitro drug release characteristics of the developed marketed tablets were studied. Dissolution data for all the experiments were highly reproducible. The dissolution of the marketed tablets indicated that more than 80% of the drug is released within 1 h, which complies with the pharmacopoeial specifications. All the selected brands of Marketed Telmisartan tablets were found be equivalents in their dissolution and there is no variation the between the tablets of all brand.
